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Abstract
Objective To explore the predictive value of MRI parame-
ters and tumour characteristics before neoadjuvant chemo-
therapy (NAC) and to compare changes in tumour size and
tumour apparent diffusion coefficient (ADC) during treat-
ment, between patients who achieved pathological complete
response (pCR) and those who did not.
Methods Approval by the Regional Ethics Committee and
written informed consent were obtained. Thirty-one patients
with invasive breast carcinoma scheduled for NAC were
enrolled (mean age, 50.7; range, 37–72). Study design
included MRI before treatment (Tp0), after four cycles of
NAC (Tp1) and before surgery (Tp2). Data in pCR versus
non-pCR groups were compared and cut-off values for pCR
prediction were evaluated.
Results Before NAC, HER2 overexpression was the single
significant predictor of pCR (p=0.006). At Tp1 ADC,
tumour size and changes in tumour size were all signifi-
cantly different in the pCR and non-pCR groups. Using
1.42×10−3 mm2/s as the cut-off value for ADC, pCR was
predicted with sensitivity and specificity of 88% and 80%,
respectively. Using a cut-off value of 83% for tumour
volume reduction, sensitivity and specificity for pCR were
91% and 80%.
Conclusion ADC, tumour size and tumour size reduction at
Tp1 were strong independent predictors of pCR.
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Introduction
Breast cancer accounts for more than 20% of all newly
diagnosed female cancers [1]. Mortality rates have
steadily been reduced because of new treatment regimens
and early detection. At the time of initial diagnosis about
7% of the patients present with advanced disease [2].
Patients diagnosed with locally advanced primary breast
cancer are considered to be at increased risk of dissemi-
nated disease. These patients now receive neoadjuvant
chemotherapy (NAC), even if the tumour is primarily
operable.
Complete response is associated with favourable outcome
[3–6]. To obtain the best possible therapeutic response it is
crucial to identify responders and non-responders/poor
responders at an early stage, thus facilitating tailored
treatment for each patient.
Tumour response during NAC has conventionally
been assessed using clinical calliper measurement, sup-
plemented with mammography and ultrasound. These
techniques have been found to be unsatisfactory, and the
accuracy of dynamic contrast-enhanced magnetic reso-
nance imaging (DCE MRI) in evaluating the extent of
residual disease has been proved to be superior to other
techniques [7–11]. As a result, MRI is increasingly being
used in response evaluation. The Response Evaluation
Criteria in Solid Tumours (RECIST) are based on
measurement of longest tumour diameter [12]. It has been
suggested that volumetric assessment of tumour size may
be a more reliable indicator of treatment response than
longest diameter, especially in cases of irregular morphol-
ogy or multifocal disease [13, 14]. The European Society
of Breast Imaging (ESOBI) recommends MRI before
NAC, halfway during treatment and after the final course
of chemotherapy [15]. There is, however, still no consen-
sus regarding optimal time points for MRI evaluation
during treatment or criteria for selecting patients likely to
benefit from a change of treatment regimen. Varying cut-off
values for diameter and volume reduction to differentiate
between poor responders and good responders have been
reported [16–18]. Currently the ESOBI recommends change
of therapy based on MRI only in non-responders and in
cases of progressive disease [15].
Dynamic contrast-enhanced MRI visualises functional
properties of the tumour in addition to morphological
depiction, allowing for detection of changes in enhance-
ment patterns preceding a reduction of tumour size.
Diffusion-weighted magnetic resonance imaging (DW
MRI) reflects the properties of randomly moving water
molecules, providing information on cell membrane integ-
rity and tumour cellularity [19]. Water diffusion is
quantitatively assessed by calculation of the apparent
diffusion coefficient (ADC). Some studies have shown a
negative correlation between pretreatment tumour ADC and
treatment response [20], whereas others have found no such
correlation [21, 22]. Increase in ADC following cytotoxic
treatment supposedly reflects loss of membrane integrity
and/or increased extracellular space [23]. In locally ad-
vanced breast cancer ADC increase early during NAC has
been shown to precede tumour volume reduction [24–26]
and may be a promising predictor of pCR [18]; the optimal
time point for assessment remains to be established.
The purpose of this study was to explore the predictive
value of MRI parameters and tumour characteristics before
NAC and to compare changes in tumour size and tumour
ADC during treatment, between patients who achieved
pathological complete response (pCR) and those who did not.
Materials and methods
Patients
Between April 2007 and October 2008 31 patients with
pathologically confirmed invasive breast cancer were
enrolled in this prospective study. Patient and tumour
characteristics are listed in Table 1.
Study design
MRI examinations, x-ray mammography and ultrasound
were carried out at three time points; before NAC (Tp0),
after the fourth cycle of NAC (Tp1) and before surgery
(Tp2). Clinical assessment and imaging were carried out
within the same week. Twenty-nine patients commenced
four NAC cycles of 5-fluoro-uracil, epirubicin and cyclo-
phosphamide (FEC) (Fig. 1). Following clinical and
radiological assessment at Tp1 10 patients were adminis-
tered two additional cycles of FEC and 18 patients were
switched to taxane-based regimens, with the addition of
trastuzumab in the cases of HER2 positivity. Two patients
had been switched to taxanes and trastuzumab after 3
courses of FEC, because of poor response and side effects.
At Tp2 21 patients underwent MRI. This final assessment
was performed 1–2 days before surgery.
MR imaging
MRI was performed using a 1.5T MRI system (ESPREE,
Siemens, Erlangen, Germany) and a phased-array bilateral
breast coil (CP Breast array coil, Siemens, Erlangen,
Germany). The MRI protocol included T1-weighted sagittal
images, T2-weighted axial images, 3D axial DCE MRI and
DW MRI (Table 2). DW MRI was acquired using b-values
of 100, 250 and 800 s/mm2. DW MRI was performed
before DCE MRI. DCE MRI was acquired every 85 s, one
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series before contrast medium administration and five post-
contrast series. The contrast agent gadopentetate dimeglumine
(Magnevist®, Schering, Berlin, Germany) was administered
at a dosage of 0.1 mmol/kg body weight.
Radiological assessment and clinical reading
The mammograms were double-read by two radiologists.
Ultrasound was performed by a trained radiologist, after
having read the mammograms. Tumour was measured in
two planes if possible. Maximum diameters were used for
comparing different techniques.
The MRI examinations were reviewed in a double-
reading by radiologists with 5, 6 and 12 years’ breast MRI
experience. Morphological assessment was made of tumour
extent, obtaining maximum diameter in the axial plane,
according to RECIST [12], and the corresponding orthog-
onal diameter. Craniocaudal diameter was determined on
multiplanar reconstructed (MPR) images in the coronal or
sagittal plane. All measurements were performed on subtrac-
Table 1 Patient and tumour characteristics
Patient Age Parity Menopause Initial clinical
tumour size (cm)
Type Grade Receptor status Lymph node
status
Pathological
response
ER PgR HER2
1 48 2 Pre 5.0 IDC 2.0 + − + + pCR
2 68 3 Post 6.0 IDC 2.0 + + − − Non-pCR
3 39 1 Pre 6.5 IDC 3.0 − − − + Non-pCR
4 55 3 Post 6.0 ILC 2.0 + + − + Non-pCR
5 47 2 Pre 5.0 IDC 3.0 + + − − Non-pCR
6 66 2 Post 9.0 IDC 3.0 + + NA + Non-pCR
7 51 3 Pre 6.0 IDC 2.0 + + − − Non-pCR
8 50 4 Post 6.0 IDC 2.0 − − + − pCR
9 42 2 Pre 7.0 IDC 3.0 − − − + Non-pCR
10 46 3 Pre 8.5 IDC NA − − + + pCR
11 46 0 Pre 6.5 IDC NA + + − − Non-pCR
12 45 2 Pre 5.5 IDC NA + + + NA pCR
13 52 2 Post 8.0 ILC 2.0 + + − + Non-pCR
14 41 2 Pre 5.3 IDC 3.0 + + − + Non-pCR
15 72 2 Post 10.0 IDC 3.0 − − − + Non-pCR
16 52 2 Pre 11.0 IDC 2.0 + − − + Non-pCR
17 52 2 Post 7.0 ILC 3.0 − − − + pCR
18 57 2 Post 5.5 ILC 3.0 + − − − pCR
19 55 2 Post 7.0 IDC 3.0 − − − + Non-pCR
20 47 3 Pre 6.5 IDC 2.0 + + − − Non-pCR
21 37 3 Pre 7.0 IDC 2.0 − − + − pCR
22 49 2 Pre 5.0 IDC 3.0 − + + − pCR
23 45 2 Pre 5.5 IDC 2.0 + + − − Non-pCR
24 66 3 Post 6.0 ILC 2.0 + + + − Non-pCR
25 53 2 Post 6.5 ILC 2.0 + + − − Non-pCR
26 53 2 Post 7.0 IDC 2.0 + + + − pCR
27R 57 3 Post 10.0 IDC 3.0 − − + + pCR
27L 4.5 IDC 2.0 + + − − pCR
28 46 2 Post 11.0 IDC 2.0 + − − + NA
29 37 0 Pre NA ILC 2.0 + + − + NA
30 57 3 post 9.0 IDC 2.0 − − + + Non-pCR
31 42 3 Pre 6.0 IDC 2.0 + + + NA Non-pCR
Pathological diagnosis at baseline was based on histopathological examination of core biopsies
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER estrogen receptor, PgR progesterone receptor, pCR pathological complete
response, NA not applicable
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tion images. Tumour volumes (Vcalc) were calculated using
the ellipsoid formula, whereas segmented tumour volumes
(Vseg) were obtained using a semi-automated segmenta-
tion algorithm based on thresholding of the enhancement
curve [21].
At Tp2 six cases were reported as ‘not measurable’ at
MRI. The reports were in these cases ambiguous, reporting
‘not measurable because of scattered enhancement’ or ‘not
measurable tumour with benign enhancement pattern’. The
reporting radiologists reviewed these cases and categorised
them as either residual tumour not present (complete
response (CR)) or residual tumour present (non-CR). At
the time of the second reading the radiologists were blinded
to the results of the pathological examination after surgery.
Post-processing of the DW MRI was performed using the
commercially available nICE software package (Nordic
NeuroLab, Bergen, Norway). ADC maps were calculated
using a mono-exponential approach and all three b-values.
Mean ADC for each breast tumour was obtained by manually
drawing a region of interest (ROI) on the ADC map best
depicting the tumour. DCE MRI and native 800 s/mm2 DW
MR images were used to guide positioning of the ROI within
the solid part of the tumour, avoiding tumour borders and
areas of necrosis.
Enrolled
(n = 31)
Neoadjuvant chemotherapy 
(NAC)
(4 x FEC-100, n = 28)
( 4 x FEC-60, n = 1)
Hormone therapy
(Letrozol, n = 2)
Toxicity
(n = 1)
Did not complete NAC
(n = 2)
NAC
(Taxans+herceptin, n = 8)
NAC 
(Taxans, n = 10)
Surgery
Ablation (n = 28)
BCS (n = 1)
Pathological evaluation*
pCR = 11
Non-pCR = 19
MRI Tp1
(n = 27)
Metstatic disease
(n = 1)
Poor response
(n = 1)
MRI Tp0
(n = 31)
NAC
(FEC-100, n = 9)
(FEC-60, n = 1)
MRI Tp2
(n = 21)
Incompliance
(n = 3)
Logistics
(n = 3)
Metastatic disease
(n = 1)
Fig. 1 Study progress-flow
chart. NAC, neoadjuvant che-
motherapy; FEC, 5-fluoro-
uracil, epirubicin and cyclo-
phosphamide; MRI, magnetic
resonance imaging; BCS, breast
conservation surgery; pCR,
pathological complete response;
time points Tp0, Tp1 and Tp2.
FEC: 5-fluoro-uracil (600 mg/
m2), epirubicin (100 or 60 mg/
m2) and cyclophosphamide
(600 mg/m2) administered every
3 weeks. Taxane-based regi-
mens: 4 cycles of docetaxel
(100 mg/m2) administered every
3 weeks or paclitaxel (80 mg/
m2) weekly for 12 weeks, with
the addition of trastuzumab in
the cases of HER2 positivity
(initial dose 8 mg/kg, followed
by 6 mg/kg every 3 weeks).
Number of days from Tp0 to
surgery was 167 (range, 128–
203). 28 patients underwent
mastectomy and axillary lymph
node dissection, followed by
loco-regional radiotherapy, one
patient chose breast-conserving
surgery. Owing to metastatic
disease 2 patients were not sub-
jected to surgical treatment. *
The number of lesions evaluable
for pathological response is one
more than the number of
patients undergoing surgery be-
cause of one patient having
bilateral disease
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Pathological response evaluation
Treatment response was determined by histopathological
examination of the surgical specimen. Pathological com-
plete response was defined as absence of invasive cancer
and non-pCR defined as residual invasive tumour of any
size, regardless of the presence of ductal carcinoma in situ
(DCIS) [27].
Statistical analysis
All statistical analysis was performed using SPSS version
16.0 (SPSS Inc., Chicago, IL, USA). Groups were compared
using the non-parametric two-sided Mann-Whitney U test
and Spearman’s rank correlation coefficient. Categorical
variables were compared using the two-sided Fisher’s exact
test. Performance for the different parameters in differenti-
ating between pCR and non-pCR patients was assessed by
creating receiver operating characteristic (ROC) curves and
comparing the area under the curves (AUCs). Significance
level was set at 5%.
Results
MRI assessed treatment response
Figure 2 shows MR images from one patient who obtained
pCR and one patient who did not. Changes in tumour size
during treatment are shown in Fig. 3. Before treatment, mean
longest tumour diameter, Vcalc and Vseg, were 5.4 cm,
41.2 cm3 and 27.8 cm3, respectively. At Tp1 mean tumour
size reductions were 59%, 76% and 78% for longest diameter,
Vcalc and Vseg, respectively. Vcalc was significantly larger than
Vseg (p=0.004) at Tp0, but there was a strong correlation
between the two tumour volumes both at Tp0 (r=0.900, p<
0.001) and at Tp1 (r=0.827, p<0.001). At Tp2 mean tumour
size reduction from baseline was 68%, 89% and 93%
measured as longest diameter, Vcalc and Vseg, respectively.
Before treatment mean tumour ADCwas 1.1×10−3 mm2/s,
and there was no difference between the pCR and the non-
pCR groups. Tumour ADC at Tp0 and Tp1 are shown in
Fig. 4. It is noted that the non-pCR patient with a marked
ADC increase (44%)was a near-pCR, pathological assessment
showed residual tumour of 1.5 mm. Compared with baseline
values, mean tumour ADC for the entire study population was
significantly increased at Tp1 (1.4×10−3 mm2/s, p<0.001).
Furthermore, mean tumour ADC in the pCR group (1.7×
10−3 mm2/s; range, 1.0–2.1×10−3 mm2/s) was significantly
higher than the mean value for the non-pCR group (1.2×
10−3 mm2/s; range, 0.9–1.7×10−3 mm2/s) (p=0.022).
Pathological examination
Eleven specimens that revealed no invasive tumour were
classified as pCR; 6 of these showed DCIS. Seventeen
specimens were classified as non-pCR with pathological
residual tumour ranging from 1.5 to 80 mm; 6 patients also
showed DCIS. Owing to scattered tumour growth, diameter
measurements were not obtained from 4 of the specimens.
Correlation between imaging techniques and pathological
examination
Correlation between maximum tumour diameter measured
at pathology and obtained from imaging at Tp2 was not
MRI sequence Sagittal TSE
T1-weighted
MRI
Axial TSE
T2-weighted
MRI
Axial
single-shot
DW SE EPI
3D-axial
DCE MRIMRI parameter
Echo time (ms) 9.4 80 10300 1.43
Repetition time (ms) 666 4570 126 4.37
Inversion time (ms) 190
Flip angle 12
Slice thickness (mm) 4 3 4 1
Slice gap (mm) 1 0 2
Number of slices 30 50 26 160
Number of excitations 1 1 3 1
Field of view (mm x mm) 220×220 340×340 360×195 320×320
Image matrix 256×256 512×512 192×104 384×307×160
Bandwidth (Hz/pixel) 220 220 1240 345
Turbo factor 5 17
Acceleration factor (GRAPPA) 2
b-values (s/mm2) 100, 250 and 800
Table 2 Magnetic resonance
imaging (MRI) protocol and
sequence parameters
MRI magnetic resonance imag-
ing, TSE turbo spin-echo, SE
EPI spin-echo echo planar
imaging, DCE dynamic
contrast-enhanced
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significant for mammography (r=0.46, p=0.21, n=9), but
was significant for ultrasound (r=0.59, p=0.01, n=18) and
MRI (r=0.87, p<0.001, n=15).
MRI accuracy
The diagnostic accuracy of MRI for pathological response
at Tp2 are summarised in Table 3. The overall MRI
accuracy was 77%. 73% (8/11) of HER2-positive lesions
obtained pCR. The response rate for HER2-negative lesions
was 18% (3/17). Prediction of pCR (negative predictive
value) in the HER2-positive group was 100% versus 50%
in the HER2-negative group.
The discordance can in the cases of false positives be
explained by the presence of DCIS. Patient 12 showed
residual tumour of 9 mm at MRI before surgery, at
pathological examination 9 mm DCIS. Patients 8 and 10
were categorised as ‘residual tumour present, not measur-
able’, at MRI, pathological examination showed DCIS. All
three obtained pCR but with DCIS present. One false
negative case had pathologically minimal residual disease
of 1.5 mm. The other false negative had not measurable
Fig. 2 Axial greyscale subtraction MR images and colour-coded
ADC maps from a patient obtaining pCR (panel a) and a patient not
responding to neoadjuvant chemotherapy (panel b) before treatment
(left column), after 4 cycles of neoadjuvant therapy (middle column)
and before surgery (right column). Both patients had locally advanced
invasive ductal carcinoma grade 3. The responding patient showed a
55% reduction in longest tumour diameter at MRI after 4 cycles of
NAC. In the non-responding patient tumour diameter increased by
5%. Tumour ADC increased by 155% between Tp0 (0.80×10-3 mm2/
s) and Tp1 (2.01×10−3 mm2/s) in the responding patient, but remained
unchanged in the non-responder (1.21×10−3 mm2/s and 1.35×10−3 mm2/s
at Tp0 and Tp1 respectively)
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tumour at MRI, whereas pathological evaluation showed
scattered tumour growth.
Prediction of pCR-pretreatment tumour characteristics
Analysing baseline data, we found that HER2 overexpression
was the only significant predictor of pCR; odds ratio of 12.4
(95% CI, 2.1–72.5; p=0.006).
Prediction of pCR-early changes in tumor size
Including all 26 patients, AUC for pCR prediction at Tp1
was 0.78, 0.82 and 0.76 for reduction of tumour
diameter, Vcalc and Vseg, respectively. For the patients
who were switched to taxane-based regimens after Tp1
(n=17) the corresponding AUCs were 0.86, 0.89 and 0.86,
respectively. For the patients who received 6 cycles of
FEC, AUC was not significantly different from the
reference line, probably due to the limited number of
patients (n=9). Despite the slight differences in AUC
between the taxane group and the study population as a
whole, we chose to include all patients in the further
analyses.
At Tp1 MRI assessed longest tumour diameter and
Vcalc were significantly different between patients achiev-
ing pCR and those who did not (Table 4). Percentage
changes in all MRI assessed tumour sizes also signifi-
cantly correlated with pathological outcome, change in
Fig. 3 Tumour size (longest diameter (a), calculated tumour volume
according to the ellipsoid formula, Vcalc, (b) and semi-automatic
segmented tumour volume Vseg (c)) before treatment (Tp0), after 4
cycles of neoadjuvant treatment (Tp1) and 1–2 days before final surgery
(Tp2) for the 29 patients receiving neoadjuvant chemotherapy. Patients
who did obtain a pathological complete response (●, n=10 (11 lesions)),
those who did not (Δ, n=17) and those who did not have surgical
treatment (×, n=2). Vseg includes previously published data [21]
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Vcalc showing the strongest predictive value (p<0.001).
Sensitivity and specificity for positive prediction of pCR,
as a function of varying cut-off values for MRI assessed
tumour size reductions at Tp1 are illustrated in Fig. 5.
For correct prediction of pCR based on tumour size
reduction, the highest combined sensitivity (91%) and
specificity (80%) were obtained using a cut-off of 83%
reduction in Vcalc
Prediction of pCR-early changes in ADC
The AUC for pCR prediction at Tp1 based on tumour ADC
was larger for the patients who were switched to taxane-based
regimens (AUC=0.95, n=15) than for the entire study
population (AUC=0.80, n=22). We chose to analyse the
predictive value of ADC data for the study population as a
whole, similar to the approach chosen for tumour measure-
ments. At Tp1 ADC values were significantly different in the
pCR and non-pCR groups (p=0.02), whereas ADC increase
was not (Table 4). Figure 6 shows the sensitivity and
specificity of pCR prediction using different cut-off values
for ADC (a) and percentage ADC increase (b) at Tp1. For
tumour ADC, high combined sensitivity (88%) and specific-
ity (80%) were obtained using a cut-off of 1.42×10−3 mm2/s.
Discussion
Pathological complete response is the ultimate goal for
NAC as it strongly correlates with a favourable prognosis
[4–7]. In this study HER2 overexpression was the only
baseline parameter showing significant correlation with
pCR. After 4 cycles of NAC changes in tumour size and
tumour ADC were independent and significant strong
predictors of pathological outcome.
The accuracy of MRI for detecting residual disease was
80%. This is in accordance with previously reported studies
[28, 29]. The discordance between MRI and the patholog-
ical result can partly be explained by our choice of
pathological categories, i.e. pCR defined as absence of
invasive tumour of any size, regardless of DCIS. In some
studies DCIS is defined as residual tumour [30], in other
studies pCR and near-pCR are the same category [16]. All
three false positives in our study were cases in which DCIS
was present. This is comparable to previous results, and it is
stated that these discordances most likely will not bear
negative clinical consequences [11]. Although the presence
of DCIS does not affect long-term outcome [27], DCIS has
been shown to increase the risk of ipsilateral breast tumour
recurrence and should therefore be diagnosed and resected
[11]. Regarding our false negative case with minimal
residual disease: this case is near-pCR and will have a
Fig. 4 Breast tumour ADC before treatment (Tp0) and after 4 cycles
of neoadjuvant chemotherapy (Tp1) for patients obtaining pCR (●, n=
11), those who did not (Δ, n=17) and those who did not have surgical
treatment (×, n=1). At Tp0, ADC values were obtained from 27
lesions in 27 patients. At Tp1, the number of lesions from which ADC
could be obtained was reduced to 22 due to image artefacts, scattered
tumour growth or minimal disease/complete response. Tumour ADC
includes previously published data [21]
Table 3 Overall performance of MRI for prediction of pathological response
Pathology  
Non-pCR pCR
Non-CR 
True positive (TP) 
12 
False positive (FP) 
3 
 Positive predictive value (PPV) 
      PPV = TP / (TP+FP) = 80% 
MRI
CR 
False negative (FN) 
2 
True negative (TN) 
5 
 Negative predictive value (NPV) 
     NPV = TN / (FN+TN) = 71% 
Sensitivity = 
TP / (TP+FN) = 86% 
Specificity = 
TN / (FP+TN) = 63% 
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similar prognosis to that of a pCR case as it has been shown
that prognosis is the same for pCR and ‘near-pCR’ patients,
the prognostic factor being total tumour burden [28, 29].
Despite superior accuracy compared with other imaging
techniques, MRI still has limitations, mainly by not
revealing residual tumour in a scattered pattern as seen in
lobular carcinomas and after shrinkage of multifocal
tumours [29]. In our study, only one of these cases was a
false negative, the other cases were correctly reported as
non-CR. The exclusion of such cases, as seen in some
studies, would probably increase MRI accuracy.
In our study population there was a significantly higher
pCR rate in the HER2-positive patients compared with the
HER2-negative patients; prediction of pCR in the HER2-
positive group was 100%, versus 50% in the HER2-
negative group. A previous study has showed increased
MRI accuracy in the HER2-positive subgroup [28],
whereas another recent study showed lower MRI accuracy
in HER2-positive patients [30]. It has been suggested that
the conflicting reports on HER2 positivity affecting MRI
accuracy may be attributed to the use of trastuzumab; in the
study showing increased accuracy trastuzumab was used. In
our study, 8 HER2-positive patients were switched to
taxanes and trastuzumab, and 5 of these lesions obtained
pCR. The 3 HER2-positive patients who received 6 cycles
of FEC also obtained pCR. Five of 6 patients receiving
trastuzumab were correctly classified at preoperative MRI,
whereas two HER2-positive patients receiving 6 FEC
cycles were false positives.
This study showed no significant correlation between
measurements at mammography and measurements at
pathological examination. Correlation between ultrasound
and pathological examination was significant, albeit much
Table 4 Individual magnetic resonance imaging (MRI) parameters
versus pathological response
Continuous parameters Mann-Whitney U test
Mean p
pCR non-pCR
MRI at Tp0
Longest tumour diameter (cm) 4.6 5.9 .056
Vcalc (cm
3) 26.7 48.0 .213
Vseg (cm
3) 20.3 29.3 .525
ADC (x10−3 mm2/s) 1.1 1.1 .693
MRI at Tp1
Longest tumour diameter (cm) 1.1 3.9 .013
Longest tumour diameter reduction (cm) 59.2 34.0 .018
Vcalc (cm
3) 2.5 23.2 .014
Vcalc reduction 91.7 64.5 .006
Vseg (cm
3) 2.0 11.3 .093
Vseg reduction (%) 93.1 67.2 .050
ADC (x10−3 mm2/s) 1.7 1.3 .022
ADC increase (%) 54.7 18.5 .111
Fig. 5 Specificity (─) and
sensitivity (∙∙∙∙) for prediction
of pCR at different cut-off
values of MRI tumour size
reduction at Tp1
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lower than for MRI. Moreover, difficulties in obtaining
measurements at both mammography and ultrasound
severely diminish the clinical value of these examina-
tions in the neoadjuvant setting. Large and irregular
tumours make ultrasound measurements difficult before
treatment; furthermore ultrasound is in general not
recommended for response evaluation of tumours accord-
ing to RECIST, owing to problems like operator
dependency and lack of reproducibility. Fibrosis replac-
ing vital tumour tissue makes response evaluation
difficult at both mammography and ultrasound. As stated
in the European Guidelines, MRI should be the method
of choice in response evaluation.
Radiological assessment should assist the oncologist
in differentiating the patients who are likely to achieve
pCR with the ongoing treatment from those who will
benefit from changing treatment regimen. Known pre-
dictors of pCR to NAC include tumour size, histological
grade, hormone-receptor status and HER2 status, among
others. Univariate analyses showed that HER2 positivity
was a strong predictive factor of pCR at baseline.
Different treatment regimens and the limited number of
patients represent limitations in our study. However, our
data indicate that HER2 overexpression may be a
positive predictive factor regardless of trastuzumab
treatment. HER2-positive patients also had a stronger
increase in ADC at Tp1, compared with the HER2-
negative patients. ADC increase emerges in our study as
an independent predictive factor at Tp1, i.e. before any
patients received trastuzumab.
Tumour ADC at Tp1 was significantly higher in the
pCR group compared with the non-pCR group. Varying
cut-off ADC values at Tp1 were used to investigate
pCR prediction. A study has reported sensitivity and
specificity of 79% and 80% using a cut-off value of
23.8% in percentage ADC change following 3 cycles of
NAC [26]. We found high sensitivity (88%) and specific-
ity (80%) using a cut-off ADC of 1.42×10−3 mm2/s.
Whereas ADC values at Tp1 were significantly different
in the pCR/non-pCR groups, percentage ADC increase
was not. Our data indicate that there may be a threshold
value for ADC, i.e. that ADC above this threshold is
required to obtain pCR prediction. It should be noted that
the cut-off ADC will depend on the choice of imaging
protocol and b-values.
In our study a single ROI was used for assessment of
tumour ADC. Using this approach the sampled region
may not be representative for the whole tumour.
However, sampling of the whole tumour volume would
inevitably include necrosis and neighbouring non-
cancerous tissue. We chose to place the ROI within the
most viable and solid part of the tumour in order to
exclude tumour necrosis and minimize partial volume
effects from tumour borders.
At Tp1 MRI assessed tumour size and percentage
change in longest diameter and Vcalc significantly correlat-
ed with pCR, Vcalc reduction being the strongest predictor.
With a cut-off of 83% reduction in Vcalc, sensitivity and
specificity for pCR were 91% and 80%, respectively. It
should be noted that lower cut-off values may be optimal if
evaluation takes place earlier in the course of treatment.
Vseg was a less sensitive pCR predictor than Vcalc. After the
onset of therapy, contrast enhancement in tumour tissue is
altered and the enhancement may resemble that of benign
breast tissue. Thus, threshold-based segmentation proce-
dures run the inherent risk of underestimating tumour burden
during and after treatment. However, reduction in Vcalc and
Vseg showed a significant correlation at Tp1, indicating the
potential of time-saving automatic procedures.
The goal of monitoring the effect of NAC should be to
discriminate between responders and non-responders early in
the treatment and in a reliable way. It may be argued that MRI
after 4 cycles is not an optimal time point for response
evaluation during treatment. There are numerous studies
reporting ADC increases early in the treatment, whereas
depiction of significant size reduction has been reported after
2, 3 and 4 cycles [17, 24–26]. Our study protocol was made in
collaboration with oncologists in our institution, and MRI
Fig. 6 Specificity (─) and sen-
sitivity (∙∙∙∙) for prediction of
pCR for different cut-off values
of ADC (a) and ADC increase
(b) at Tp1
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after 4 cycles was chosen because of the emphasis on the need
for reliable response evaluation. After 4 cycles the treatment
regimen may still be changed to optimise the response.
Optimal timing for response monitoring will depend on the
anticipated treatment response. Larger studies are required to
establish the optimal time point for response evaluation.
Conclusion
Our study confirms that MRI is superior to the other
techniques and should be the chosen method of response
evaluation and prediction of pCR before surgery. After four
cycles of NAC, ADC, tumour size and tumour size
reduction showed predictive value for pCR, ADC and
calculated tumour volume being the strongest predictors.
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